口咽癌合并第二原发肿瘤的临床特征及预后分析  

Clinical characteristics and efficacy of oropharyngeal carcinoma with secondary primary tumor

作　　者：何美霖 易俊林[1] HE Meilin;YI Junlin(Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China)

机构地区：[1]国家癌症中心,肿瘤临床研究中心,北京协和医学院中国医学科学院肿瘤医院放疗科,北京100021

出　　处：《临床耳鼻咽喉头颈外科杂志》2023年第9期721-728,共8页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

摘　　要：目的:在真实世界中分析口咽癌合并第二原发肿瘤的临床特征及预后。方法:回顾性分析2010年1月至2020年12月中国医学科学院肿瘤医院收治的468例经病理证实,排除远转移,明确p16状态的以口咽为首发肿瘤的患者,分析合并第二原发肿瘤的临床特征及预后。结果:468例初治口咽癌患者,其中p16阴性222例,中位随访时间64.3个月,66例(29.3%)发生第二原发癌,其中42例(63.6%)为同时性,24例(36.4%)为异时性,食管为最常见累及部位,p16阴性口咽癌合并同时性第二原发癌、异时性第二原发癌组和无第二原发癌3组的5年生存率(overall survival OS)分别为26.3%,57.3%和73.2%(P=0.001);第二原发癌占全组死因的11.2%(12/107),其中异时性第二原发占75.0%(9/12)。p16阳性246例,中位随访时间52.4个月,20例(8.1%)发生了第二原发癌,其中13例(65.0%)为同时性,7例(35.0%)为异时性,食管为最常见累及部位,p16阳性同时性第二原发癌组和不合并第二原发癌组4年OS分别为51.9%vs 80.7%(P=0.006);p16阳性同时性第二原发癌组和合并异时性第二原发癌组4年OS分别51.9%vs 83.3%(P=0.068)。第二原发癌占全组死因的3.8%(2/52)。结论:p16阴性口咽癌发生第二原发癌概率高于p16阳性患者。无论p16状态,合并同时性第二原发癌的生存差于不合并第二原发癌组;食管均为最常见累及部位;p16阴性口咽癌,合并异时性第二原发癌预后较好,第二原发癌是其主要死因之一。Objective:To analysis the clinical features and prognosis in oropharyngeal carcinoma with secondary primary tumor.Methods:A retrospective analysis was performed on 468 pathologically confirmed oropharyngeal cancer as the primary tumor patients with p16 status,excluded distant metastasis,and admitted to the Chinese Academy of Medical Sciences from January 2010 to December 2020.The clinical features and prognosis of the secondary primary tumor were analyzed.Results:Among 468 patients with oropharyngeal cancer treated at initial diagnosed,222 cases were P16-negative.With a median follow-up time of 64.3 months,66 cases developed second primary cancer,with an incidence of 29.3%,among which 63.6%(42/66) were synchronous and 36.4%(24/66) were heterochronous,esophagus was the most commonly involved site.The 5-year OS of p16-negative oropharyngeal carcinoma with synchronous second primary cancer,without second primary cancer and with heterogeneous second primary cancer were 26.3% and 57.3% and 73.2%(P=0.001);The second primary cancer accounted for 11.2%(12/107) of the deaths in the whole group,among them,the heterochronous second primary accounted for 75.0%(9/12).There were 246 patients with p16 positive,with a median follow-up time of 52.4 months,20 patients developed second primary cancer(8.1%).Among them,65.0%(13/20) were synchronous and 35.0%(7/20) were heterochronous.Esophagus was the most commonly involved site.The 4-year OS of p16-positive with synchronous,heterochronous and non-second primary cancer group were 51.9%,80.7% and 83.3%.Secondary primary cancer accounted for 3.8%(2/52) of all deaths in p16 positvie group.Conclusion:The incidence of second primary cancer of p16 positive and negative oropharyngeal carcinoma were different.The esophagus was the most commonly involved site regardless of p16 status.Regardless of p16 status,the survival of patients with synchronous second primary cancer was worse than those without second primary cancer.For p16-negative oropharyngeal carcinoma,the prognosis was better in pat

关 键 词：口咽肿瘤 同时性第二原发癌 异时性第二原发癌 预后 

分 类 号：R739.8[医药卫生—肿瘤]